Prospects for future therapy of HCV infection

Future Virology

Volumn 4, Issue 5, 2009, Pages 453-462

  Sakamoto, Naoya ^b   Wu, George Y ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Cyclosporine; HCV replicon system; Immune modulator; STAT C

Indexed keywords

4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; 5 CYCLOPROPYL 2 (4 FLUOROPHENYL) 6 [N (2 HYDROXYETHYL)METHANESULFONAMIDO] N METHYLBENZOFURAN 3 CARBOXAMIDE; ALBINTERFERON ALPHA2B; ALPHA INTERFERON; ANTIVIRUS AGENT; BAVITUXIMAB; BILB 1941; CASTANOSPERMINE 6 BUTYRATE; CYCLOSPORIN A; CYCLOSPORIN A [3 N METHYL DEXTRO ALANINE 4 N ETHYLVALINE]; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; CYCLOSPORIN D; CYCLOSPORIN DERIVATIVE; IMMUNOMODULATING AGENT; IMO 2125; INFLIXIMAB; INTERLEUKIN 29; ISATORIBINE; MICRORNA; NA 255; NITAZOXANIDE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SCY 635; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE;

ANEMIA; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; AUTOIMMUNE DISEASE; BLOOD TOXICITY; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; LIVER CELL CARCINOMA; LIVER TOXICITY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 73849091624     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.09.44     Document Type: Review

References (78)

1. Alter MJ: Epidemiology of hepatitis C. Hepatology 26, S62-S65 (1997).
2. Hoofnagle JH, Di Bisceglie AM: The treatment of chronic viral hepatitis. N. Engl. J. Med. 336, 347-356 (1997).
3. Rosen HR, Gretch DR: Hepatitis C virus: current understanding and prospects for future therapies. Mol. Med. Today 5, 393-399 (1999).
4. Fried MW, Shiffman ML, Reddy KR et al.: Peginterferon a-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975-982 (2002). ■ First report of pegylated interferon (peg-IFN) monotherapy against HCV.
5. Zeuzem S, Feinman SV, Rasenack J et al.: Peginterferon a-2a in patients with chronic hepatitis C. N. Engl. J. Med. 343, 1666-1672 (2000).
6. Bartenschlager R, Lohmann V: Replication of hepatitis C virus. J. Gen. Virol. 81, 1631-1648 (2000).
7. Lohmann V, Koerner F, Koch J-O, Herian U, Theilmann L, Bartenschlager R: Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110-113 (1999). ■ Report of HCV subgenomic replicon system.
8. Tanabe Y, Sakamoto N, Enomoto N et al.: Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-α. J. Infect. Dis. 189, 1129-1139 (2004). ■ Classical report of luciferase-based HCV replicon.
9. Yokota T, Sakamoto N, Enomoto N et al.: Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. 4, 602-608 (2003). ■ Report of siRNA vector targeting HCV.
10. Wakita T, Pietschmann T, Kato T et al.: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11, 791-796 (2005). ■ Cornerstone report of robust HCV cell culture system.
11. Zhong J, Gastaminza P, Cheng G et al.: Robust hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA 102, 9294-9299 (2005).
12. Mercer DF, Schiller DE, Elliott JF et al.: Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7, 927-933 (2001).
13. Tateno C, Yoshizane Y, Saito N et al.: Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am. J. Pathol. 165, 901-912 (2004).
14. Wu GY, Konishi M, Walton CM, Olive D, Hayashi K, Wu CH: A novel immunocompetent rat model of HCV infection and hepatitis. Gastroenterology 128, 1416-1423 (2005). ■ A human liver-engrafted immune competent rat model and HCV infection.
15. Sakamoto N, Watanabe M: New therapeutic approaches to HCV. J. Gastroenterol. 44(7), 643-649 (2009).
16. Foy ELK, Wang C, Sumpter R Jr, Ikeda M, Lemon SM, Gale M Jr: Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300, 1145-1148 (2003).
17. Faucher AM, Bailey MD, Beaulieu PL et al.: Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans. Org. Lett. 6, 2901-2904 (2004).
18. Lamarre D, Anderson PC, Bailey M et al.: An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186-189 (2003).
19. Sarrazin C, Rouzier R, Wagner F et al.: SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon α-2b for genotype 1 nonresponders. Gastroenterology 132, 1270-1278 (2007).
20. Kieffer TL, Sarrazin C, Miller JS et al.: Telaprevir and pegylated interferon-α-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46, 631-639 (2007).
21. Forestier N, Reesink HW, Weegink CJ et al.: Antiviral activity of telaprevir (VX-950) and peginterferon a-2a in patients with hepatitis C. Hepatology 46, 640-648 (2007).
22. Reesink HW, Zeuzem S, Weegink CJ et al.: Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase Ib, placebo-controlled, randomized study. Gastroenterology 131, 997-1002 (2006).
23. McHutchison JG, Everson GT, Gordon SC et al.: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360, 1827-1838 (2009). ■■ First trial on protease inhibiter, peg-IFN and ribavirin triple combination in USA.
24. Hezode C, Forestier N, Dusheiko G et al.: Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360, 1839-1850 (2009). ■■ First trial on protease inhibiter, peg-IFN and ribavirin triple combination in Europe.
25. Sarrazin C, Kieffer TL, Bartels D et al.: Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132, 1767-1777 (2007).
26. Kuntzen T, Timm J, Berical A et al.: Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48, 1769-1778 (2008).
27. Kurosaki M, Enomoto N, Marumo F, Sato C: Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection. Hepatology 18, 293-1299 (1993).
28. Sakamoto N, Enomoto N, Kurosaki M, Marumo F, Sato C: Sequential change of the hypervariable region of the hepatitis C virus genome in acute infection. J. Med. Virol. 42, 103-108 (1994).
29. McCown MF, Rajyaguru S, Le Pogam S et al.: The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother. 52, 1604-1612 (2008).
30. Pockros PJ, Nelson D, Godofsky E et al.: R1626 plus peginterferon α-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 48, 385-397 (2008).
31. Pogam SL, Seshaadri A, Kosaka A et al.: No evidence of R7128 drug resistance after up to 4 weeks treatment of GT 1,2 and 3 hepatitis C virus infected individuals. J. Hepatol. 50(Suppl. 1), S348 (2009). ■ Nucleoside inhibitor of HCV-polymerase shows a high barrier to drug resistance.
32. Shi ST, Herlihy KJ, Graham JP et al.: Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 53(6), 2544-2552 (2009).
33. Erhardt A, Deterding K, Benhamou Y et al.: Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antivir. Ther. 14, 23-32 (2009).
34. Shi ST, Herlihy KJ, Graham JP et al.: In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 52, 675-683 (2008).
35. Le Pogam S, Seshaadri A, Kosaka A et al.: Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J. Antimicrob. Chemother. 61, 1205-1216 (2008).
36. Kneteman NM, Howe AY, Gao T et al.: HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology 49, 745-752 (2009).
37. Feldstein A, Kleiner D, Kravetz D, Buck M: Severe hepatocellular injury with apoptosis induced by a hepatitis C polymerase inhibitor. J. Clin. Gastroenterol. 43, 374-381 (2009).
38. Buckwold VE, Wei J, Huang Z et al.: Antiviral activity of CHO-SS cell-derived human w-interferon and other human interferons against HCV-RNA replicons and related viruses. Antiviral Res. 73, 118-125 (2007).
39. Kratz F: Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control Release 132(3), 171-183 (2008).
40. Rustgi VK: Albinterferon α-2b, a novel fusion protein of human albumin and human interferon α-2b, for chronic hepatitis C. Curr. Med. Res. Opin. 25, 991-1002 (2009). ■ Early review of Albuferon®.
41. Pagliaccetti NE, Eduardo R, Kleinstein SH, Mu XJ, Bandi P, Robek MD: Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J. Biol. Chem. 283, 30079-30089 (2008).
42. De Leede LG, Humphries JE, Bechet AC, Van Hoogdalem EJ, Verrijk R, Spencer DG: Novel controlled-release Lemna-derived IFN-a2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a Phase I clinical trial. J. Interferon Cytokine Res. 28, 113-122 (2008). ■ Phase I report of controlled release interferon, Locteron®.
43. E Herrmann, S Zeuzem, I Dzyublyk et al.: Viral kinetics during treatment with a controlled-release recombinant interferon α 2b in genotype 1 chronic hepatitis C patients. Presented at: 43rd Annual Meeting of the European Association for the Study of the Liver (EASL 2008). Milan, Italy, 23-27 April 2008.
44. Heil F, Hemmi H, Hochrein H et al.: Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303, 1526-1529 (2004).
45. Horsmans Y, Berg T, Desager JP et al.: Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42, 724-731 (2005).
46. Agrawal S, Kandimalla ER: Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem. Soc. Trans. 35, 1461-1467 (2007).
47. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T: Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 20, 6877-6888 (2001). ■ First report of siRNA gene silencing.
48. Randall G, Grakoui A, Rice CM: Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc. Natl Acad. Sci. USA 100, 235-240 (2003).
49. Sakamoto N, Tanabe Y, Yokota T et al.: Inhibition of hepatitis C virus infection and expression in vitro and in vivo by recombinant adenovirus expressing short hairpin RNA. J. Gastroenterol. Hepatol. 23, 1437-1447 (2008).
50. Tomari Y, Zamore PD: Perspective: machines for RNAi. Genes Dev. 19, 517-529 (2005).
51. Zeng Y, Yi R, Cullen BR: MiRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc. Natl Acad. Sci. USA 100, 9779-9784 (2003).
52. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P: Modulation of hepatitis C virus RNA abundance by a liver-specific miRNA. Science 309, 1577-1581 (2005).
53. Shan Y, Zheng J, Lambrecht RW, Bonkovsky HL: Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology 133, 1166-1174 (2007). ■ miRNA-122 is essential for hepatocyte differentiation and for HCV replication.
54. Randall G, Panis M, Cooper JD et al.: Cellular cofactors affecting hepatitis C virus infection and replication. Proc. Natl Acad. Sci. USA 104, 12884-12889 (2007).
55. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W: Decreased levels of miRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat. Med. 15, 31-33 (2009).
56. Pedersen IM, Cheng G, Wieland S et al.: Interferon modulation of cellular miRNAs as an antiviral mechanism. Nature 449, 919-922 (2007).
57. Borel JF, Feurer C, Gubler HU, Stahelin H: Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6, 468-475 (1976).
58. Matsuda S, Koyasu S: Mechanisms of action of cyclosporine. Immunopharmacology 47, 119-125 (2000).
59. Nilsson B, Anderson S: Proper and improper folding of proteins in the cellular environment. Annu. Rev. Microbiol. 45, 607-635 (1991).
60. Brandts JF, Halvorson HR, Brennan M: Consideration of the possibility that the slow step in protein denaturation reactions is due to cis-trans isomerism of proline residues. Biochemistry 14, 4953-4963 (1975).
61. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K: Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38, 1282-1288 (2003).
62. Nakagawa M, Sakamoto N, Enomoto N et al.: Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem. Biophys. Res. Commun. 313, 42-47 (2004). ■ In vitro report that cyclosporin A specifically suppress HCV replicon.
63. Nakagawa M, Sakamoto N, Tanabe Y et al.: Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 129, 1031-1041 (2005). ■■ First report that cellular cyclophilins are essential for HCV replication and are targeted by cyclosporine A.
64. Chatterji U, Bobardt M, Selvarajah S et al.: The isomerase active site of cyclophilin A is critical for HCV replication. J. Biol. Chem. 284(25), 16998-17005 (2009).
65. Billich A, Hammerschmid F, Peichl P et al.: Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions. J. Virol. 69, 2451-2461 (1995).
66. Paeshuyse J, Kaul A, De Clercq E et al.: The non-immunosuppressive cyclosporin Debio 025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43, 761-770 (2006).
67. Flisiak R, Horban A, Gallay P et al.: The cyclophilin inhibitor Debio 025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 47, 817-826 (2008). ■ First report of Debio 025 monotherapy for HCV-HIV coinfected patients.
68. Coelmont L, Kaptein S, Paeshuyse J et al.: Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob. Agents Chemother. 53, 967-976 (2009).
69. Flisiak R, Feinman SV, Jablkowski M et al.: The cyclophilin inhibitor Debio 025 combined with PEG IFNa2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 49(5), 1460-1468 (2009). ■■ Clinical trial of Debio 025 plus peg-IFN combination therapy.
70. Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS: Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob. Agents Chemother. 52, 4069-4071 (2008).
71. Korba BE, Montero AB, Farrar K et al.: Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res. 77, 56-63 (2008). ■ In vitro effect of nitazoxanide against HCV and HBV replication.
72. Rossignol JF, Kabil SM, El-Gohary Y, Elfert A, Keeffe EB: Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol. Ther. 28, 574-580 (2008). ■■ Clinical trial of nitazoxanide monotherapy for HCV.
73. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB: Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 136, 856-862 (2009). ■■ Preliminary report of Phase II trial of nitazoxanide, peg-IFN and ribavirin combination therapy.
74. Sakamoto H, Okamoto K, Aoki M et al.: Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat. Chem. Biol. 1, 333-337 (2005).
75. Soares MM, King SW, Thorpe PE: Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat. Med. 14, 1357-1362 (2008).
76. Tomillero A, Moral MA: Gateways to clinical trials. Methods Find. Exp. Clin. Pharmacol. 30, 643-672 (2008).
77. Durantel D, Alotte C, Zoulim F: Glucosidase inhibitors as antiviral agents for hepatitis B and C. Curr. Opin. Investig. Drugs 8, 125-129 (2007).
78. ClinicalTrials.gov. www.clinicaltrials.gov